# Beyang Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beyang-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.beyangtx.com
- Total disclosed funding: $30M
- Latest round: Series A (Jul 31, 2026)
- Investors on record: 11

## About

Based in Shanghai, China, and established in 2021, Beyang Therapeutics Co., Ltd., trading as Beyang Therapeutics, is a pharmaceutical company that focuses on the R&D of new drugs for ocular diseases and cancer. Qiyue Hu, the company's CEO, has more than 20 years of pharmaceutical research and development, and management experience, who once worked 12 years in Pfizer and 9 years in Hengrui, respectively. As well as, he has 38 invention patents, and 30 peer-reviewed research articles. In July 2026, Beyang Therapeutics raised nearly CNY 200 million in Series A funding co-led by Legend Capital and Shanghai Industrial Investment, with participation from China Medical System Holdings Limited, Tingyu Fund, Shanghai Sci-Tech Innovation Center Capital, IFSC, Root and YuanBio Venture.

Beyond Therapeutics Co., Ltd. established a proprietary computer-accelerated integrated drug discovery platform, ExCEED, which can improve the R&D efficiency and shortens the time from leads to preclinical candidates. It developed new drugs include BT01001, and BT01002. The BT01001 is a small molecule eye drop for the targeted treatment of fundus disorders. And the BT01002 is a small molecule inhibitor for the relapsed refractory subtype of high-risk leukaemia.

The company's revenue is generated by providing a proprietary computer-accelerated integrated drug discovery platform, ExCEED, which utilizes novel molecular generation and optimization method MMPT and in silico DMPK simulation prediction to guide the discovery and development of preclinical candidate molecules. 

The company will use the latest funding to accelerate the technological iteration of the company's core AI+molecular design and optimization platform (ExCEED), advance the clinical and preclinical development of key projects, and further improve the construction of its international R&D and business teams.

## Funding rounds

- Series A, Jul 31, 2026, $30M — Legend Capital, YuanBio Venture, IFSC, Shanghai Sci-Tech Innovation Center Capital, Shanghai Industrial Investment, Root Venture Partners, Tingyu Fund, China Medical System Holdings Limited
- Angel, Nov 10, 2021 — Oriza Holdings, YuanBio Venture, Baidu Ventures, E Link Ventures

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Angel
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel, Series A
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Angel
- E Link Ventures (https://capitalatlas.ai/funds/e-link-ventures) — Angel
- Legend Capital — Series A
- IFSC (https://capitalatlas.ai/funds/ifsc) — Series A
- Shanghai Sci-Tech Innovation Center Capital (https://capitalatlas.ai/funds/shanghai-sci-tech-innovation-center-capital) — Series A
- Shanghai Industrial Investment (https://capitalatlas.ai/funds/shanghai-industrial-investment) — Series A
- Root Venture Partners (https://capitalatlas.ai/funds/root-venture-partners) — Series A
- Tingyu Fund — Series A
- China Medical System Holdings Limited — Series A